EMERYVILLE, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Bradley S. Galer, M.D., Executive Vice President and CMO, will present a corporate update at the LEERINK Partners 5th Annual Global Healthcare Conference in New York, NY, on February 10, 2016.
|LEERINK Partners 5th Annual Global Healthcare Conference -- Zogenix Presentation Details|
|Date:||Wednesday, February 10, 2016|
|Time:||10:40 am Eastern Time / 7:40 am Pacific Time|
|Location:||New York, NY - The Waldorf Astoria Hotel, Metropolitan Suite|
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | Andrew@lifesciadvisors.com